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https://doi.org/10.1016/j.celrep.2020.107667SUMMARYHuman guanylate binding protein 1 (hGBP1) belongs to the dynamin superfamily of GTPases and conveys
host defense against intracellular bacteria and parasites. During infection, hGBP1 is recruited to path-
ogen-containing vacuoles, such as Chlamydia trachomatis inclusions, restricts pathogenic growth, and in-
duces the activation of the inflammasome pathway. hGBP1 has a unique catalytic activity to hydrolyze gua-
nosine triphosphate (GTP) to guanosine monophosphate (GMP) in two consecutive cleavage steps.
However, the functional significance of this activity in host defense remains elusive. Here, we generate a
structure-guided mutant that specifically abrogates GMP production, while maintaining fast cooperative
GTP hydrolysis. Complementation experiments in humanmonocytes/macrophages show that hGBP1-medi-
ated GMP production is dispensable for restricting Chlamydia trachomatis growth but is necessary for in-
flammasome activation. Mechanistically, GMP is catabolized to uric acid, which in turn activates the
NLRP3 inflammasome. Our study demonstrates that the unique enzymology of hGBP1 coordinates bacterial
growth restriction and inflammasome signaling.INTRODUCTION
Intracellular bacteria retain a fine balance between survival and
detection by the host. The recognition of distinct pathogenic sig-
natures, so-called pathogen-associated molecular patterns
(PAMPs), is essential for the host organism to distinguish self
from an invading pathogen and to consequently activate an
effective immune response (Kim et al., 2016). Chlamydia tracho-
matis (C. trachomatis), an obligate intracellular Gram-negative
bacterium, is the most common cause of sexually transmitted
diseases (Elwell et al., 2016). C. trachomatis enters the host
cell within a membranous compartment, and in order to avoid
detection, it is compelled to reside within this pathogen-contain-
ing vacuole (PCV) throughout its life cycle (Kumar and Valdivia,
2009). Thus, C. trachomatis infections often remain undetected
by the host immune system. How host cells mount immunity
against such vacuolar pathogens is poorly understood.
Recently, the interferon-g (IFN-g)-induced guanylate binding
proteins (GBPs) have emerged as versatile antimicrobial agents
of cell-autonomous immunity (Kim et al., 2011). GBPs belong to
the dynamin superfamily of large GTPases. Like other dynamin-
related proteins, GBPs show nucleotide-dependent oligomeri-
zation and fast cooperative GTPase activity (Daumke andThis is an open access article under the CC BY-NPraefcke, 2016; Praefcke and McMahon, 2004). Among the
seven hGBPs, hGBP1, hGBP2, and hGBP5 exhibit a C-terminal
isoprenylation anchor that enables membrane binding (Britzen-
Laurent et al., 2010). These GBPs are recruited to PCVs or the
bacterial membrane; it is, therefore, proposed that they engage
in a membrane remodeling event that restricts pathogenic
growth (Meunier et al., 2014). In turn, the liberation of PAMPs
may be sensed by canonical and non-canonical inflammasomes
(Meunier et al., 2015; Pilla et al., 2014). The activated inflamma-
some initiates the secretion of pro-inflammatory cytokines and
chemokines that recruit effector immune cells. It also induces in-
flammatory host cell death, a process termed pyroptosis (Kan-
neganti, 2015). Accordingly, GBP-deficient cells or mice fail to
restrict pathogenic growth and display dampened inflamma-
some activation (Degrandi et al., 2013; Finethy et al., 2015; Fisch
et al., 2019; Pilla et al., 2014). How GBPs coordinate these two
processes and the exact role of GBPs in inflammasome activa-
tion have not been addressed so far.
hGBP1 has a unique catalytic property of hydrolyzing guano-
sine triphosphate (GTP) to guanosine monophosphate (GMP)
in two consecutive cleavage reactions (Praefcke et al., 1999;
Schwemmle and Staeheli, 1994). Crystal structures of the
hGBP1 GTPase domain (G-domain) reveal that the riboseCell Reports 31, 107667, May 19, 2020 ª 2020 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. The hGBP1 G68A Mutant Exhibits
an Impaired Consecutive Hydrolysis Step
(A) (Top) Superimposition of hGBP1 G-domain
structures bound to GDP$AlFx (brown; PDB: 2b92)
and GMP$AlFx (blue; PDB: 2b8w). (Bottom)
Sequence alignment of human GBP1, GBP2, and
GBP5. Position 68 is marked in red.
(B–D) GTP hydrolysis (B), GDP production (C), and
GMP production (D) of 2 mM hGBP1 WT (d), G68A
(-), K76A (:), or R48A (;) were followed by an
high-performance liquid chromatography (HPLC)-
based approach. Data represent the average of
two independent measurements ± range. Error
bars smaller than the data points are not indicated.
(E) Cooperative GTP hydrolysis rate of indicated
hGBP1 proteins obtained by plotting specific ac-
tivity against protein concentration. Data repre-
sent the average of two independent measure-
ments ± range. Error bars smaller than the data
points are not indicated.
(F) End product formation of GTP hydrolysis after
reacting with 2 mMof indicated hGBP1 proteins for
30min; n = 3. Error bars indicate the standard error
of the mean (SEM). *p < 0.05, **p < 0.01, ***p <
0.001, two-way ANOVA.
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hydrolysis. As a result, the b-phosphate occupies the position,
which was previously occupied by the g-phosphate. Thus,
GDP can be cleaved to GMP with the same catalytic machinery
(Ghosh et al., 2006). However, the functional significance of its
distinctive enzymatic property remains unknown.
To decipher this enzymatic function, we generated a struc-
ture-guided hGBP1 mutant that maintains GTP hydrolysis but
specifically abolishes the second step of the hydrolysis reaction.
Using a gene knockout (KO) system and reconstitution experi-
ments on human monocytes, we show that the second hydroly-
sis step is dispensable for bacterial restriction but is necessary
for mounting inflammasome activation.
RESULTS
The hGBP1G68AMutant Retains Fast, Cooperative GTP
Hydrolysis While Displaying Reduced GMP Production
Because the two-step cleavage mechanism of GTP to GMP by
hGBP1 requires the movement of the ribose backbone of the
cleaved GDP moiety, a point mutation in the G-domain of
hGBP1 was designed to sterically lock GDP in the nucleotide
binding site and, thus, prevent the second hydrolysis step (Fig-
ure 1A). Several glycine residues surround GTP in the catalytic
site and provide the necessary peptide backbone flexibility
that enables nucleotide relocation. Among these glycines, we2 Cell Reports 31, 107667, May 19, 2020focused on Gly68 for two reasons. First,
in the reported crystal structure (Ghosh
et al., 2006), Gly68 is in close proximity
to the ribose moiety of GDP during GTP
hydrolysis, and its mutation into a bulkier
amino acid may consequently interfere
with nucleotide displacement. Second,we compared hGBP1 to hGBP5, which can cleave GTP only to
GDP (Neun et al., 1996;Wehner andHerrmann, 2010). According
to the sequence alignment, Gly68 is substituted with alanine in
hGBP5 (Figure 1A).
The G68A mutant of hGBP1 retained a similar GTP hydrolysis
rate to that of the wild-type (WT) protein (Figure 1B). However,
the G68A mutation completely abolished GMP production (Fig-
ures 1C, 1D, and 1F). Mutations in Lys76 or His74 in the
conserved switch I region of the G-domain have been previously
shown to abrogate GMP production (Praefcke et al., 2004).
Nonetheless, unlike G68A, the K76A mutation led to a general
reduction in GTP hydrolysis (Figure 1B). Mutating Arg48, which
stabilizes the transition state of GTP hydrolysis, to alanine
completely abolished GTP hydrolysis (Figures 1B–1E), which is
also consistent with previous data (Praefcke et al., 2004).
To further compare the specific catalytic activities of the mu-
tants, we performed a detailed time- and concentration-depen-
dent enzymatic characterization. In comparison to the WT pro-
tein, we show that the dimerization-dependent GTP hydrolysis
activity of the G68A mutant was not impaired. Although the
K76A mutation retained cooperativity, this mutation led to a
4-fold decrease in the maximal GTP hydrolysis activity (Fig-
ure 1E). Collectively, among the tested hGBP1 mutants that
abolish GMP production, the G68A mutant had the most WT-
comparable GTP hydrolysis activity, and we therefore utilized
this mutant for the subsequent functional studies.
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Figure 2. hGBP1 G68A Mutant Is Able to Restrict C. trachomatis
(A) Representative images of indicated THP-1 cell lines infected with C. trachomatis at MOI of 5 for 24 h. White arrows indicate inclusions. Red, C. trachomatis.
Blue, 40,6-diamidino-2-phenylindole (DAPI). Scale bars, 20 mm.
(B and C)C. trachomatis inclusions larger (B) or smaller (C) than the size of 2-mmdiameter were quantified by scanning the nuclei (30–40 per image) of all the cells,
as indicated in (A) (n = 3).
(D) Influence of hGBP1mutants onC. trachomatis infectious progeny.C. trachomatis inclusions were isolated from the infected various THP-1 cells; the infectivity
was determined by the re-infection of HeLa 229 cells, normalized to the parental THP-1 cells.
(E) Representative images of (D). Red, C. trachomatis. Blue, DAPI.
All error bars indicate SEM. *p < 0.05, **p < 0.01, one-way ANOVA. See also Figure S1.
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Restriction of C. trachomatis
To characterize the role of the second-step GDP hydrolysis for
pathogen restriction, we knocked out hGBP1 in THP-1 cells, a
human monocyte cell line, by using CRISPR-Cas9 technology.
We then reconstituted the KO cells with lentivirus-expressed
WT hGBP1, the hGBP1 mutants, R48A or G68A, or GFP as a
negative control. The depletion of endogenous hGBP1 and the
expression of exogenous constructs were confirmed by western
blot (Figure S1A).
Parental THP-1 cells and the newly generated cell lines were
infected with C. trachomatis, followed by immunostaining
against major outer membrane protein (MOMP), an antigen of
C. trachomatis. In agreement with a previous study, hGBP1 KO
cells presented an increased number and size of C. trachomatisinclusions (Figures 2A–2C) (Al-Zeer et al., 2013). Re-expression
of WT hGBP1, but not the R48A mutant, reduced C. trachomatis
inclusions, indicating that hGBP1-mediated GTP hydrolysis is vi-
tal for C. trachomatis restriction. Surprisingly, G68A mutants
restricted C. trachomatis comparably to WT hGBP1-expressing
cells (Figures 2A–2C).
To further substantiate these findings, we tested the require-
ment of consecutive GTP hydrolysis for restricting infectious
C. trachomatis progeny by conducting a re-infection assay in
HeLa cells. hGBP1 KO cells and R48A mutants increased the
production of C. trachomatis elementary bodies, whereas WT
hGBP1-expressing cells and G68A mutants significantly
reduced their production (Figures 2D and 2E). Thus, consecutive
GTP hydrolysis is dispensable for hGBP1-mediated Chlamydia
restriction.Cell Reports 31, 107667, May 19, 2020 3
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Figure 3. The Consecutive Hydrolysis of hGBP1 Is Required for Inflammasome Activation
(A) Inflammasome activation was examined by IL-1b ELISA. Cell lines were infected with C. trachomatis at MOI of 30 for 24 h; n = 3; two-way ANOVA.
(B) Cell death was measured by measuring the release of lactate dehydrogenase in LPS + IFN-g-stimulated THP-1 cells infected withC. trachomatis at anMOI of
30 for 24 h; n = 3; two-way ANOVA.
(C) Inflammasome activation was examined by immunoblotting against caspase-1. Cell lines were infected withC. trachomatis at anMOI of 30 for 24 h. The blot is
a representative result of two independent experiments.
(D) Quantification of inflammasome ASC specks of indicated cell lines infected with C. trachomatis at an MOI of 30 for 24 h; n = 3; one-way ANOVA.
(E) Representative images of (D). Red, ASC specks. Blue, DAPI. Scale bar, 10 mm.
All error bars indicated SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.
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Inflammasome Activation
It has been previously demonstrated that GBPs are required for
inflammasome activation (Fisch et al., 2019; Man et al., 2015;
Meunier et al., 2014, 2015; Pilla et al., 2014). Inflammasome acti-
vation leads to Gasdermin D-mediated cell death (pyroptosis),
caspase-1-dependent processing, and the secretion of inter-
leukin-1b (IL-1b). We evaluated the cell death rate of C. tracho-
matis-infected THP-1 cells by measuring lactate dehydrogenase
(LDH) release and IL-1b secretion. As expected, KO cells
showed a significant reduction in IL-1b secretion and cell death
rate compared with the parental cells (Figures 3A and 3B). These4 Cell Reports 31, 107667, May 19, 2020defects were rescued by re-expression of hGBP1 WT. In
contrast, expression of the R48A mutant failed to rescue IL-1b
secretion (Figure 3A), concomitantly with unexpected increased
cell death (Figure 3B). Screening of inhibitors that target various
cell death mechanisms showed that R48A mutants died due to
necroptosis (Figure S1B). The surprising link between the
hGBP1 R48A mutation and the induction of necroptosis needs
further investigation.
Interestingly, the G68A mutant failed to secrete IL-1b and
induce cell death in an infection-dependent manner, which
was comparable with KO cells (Figures 3A and 3B). We also
examined the status of caspase-1 activation by western blotting
Report
ll
OPEN ACCESSof cell culture supernatants. In contrast to hGBP1 WT the G68A
mutant did not rescue the secretion of mature caspase-1 subunit
p20 in hGBP1 KO cells (Figure 3C). We reasoned that the
reduced secretion of caspase-1 and inflammatory cytokines
are the results of impaired inflammasome activation.
A previous study demonstrates that hGBP2 can also hydrolyze
GTP to GMP but much less efficiently than hGBP1 (10% of
hGBP1) (Neun et al., 1996). Depletion of hGBP2 in THP-1 cells
led to a non-significant marginal reduction of IL-1b release and
cell death (Figure S1C), despite an efficient knockdown (Fig-
ure S1D). Thus, activation of the inflammasome is not a general
feature of all hGBPs. Instead, it may be related to the exception-
ally high GMP production by hGBP1.
hGBP1 Activates the NLRP3 Inflammasome
hGBPs have been shown to activate the canonical nucleotide-
binding oligomerization domain (NOD-), leucine-rich repeat
(LRR-), and pyrin domain-containing protein 3 (NLRP3) inflam-
masome either directly or indirectly through the non-canonical
caspase-4-mediated pathway (Meunier et al., 2014; Pilla et al.,
2014). To prove whether consecutive GTP hydrolysis is required
for inflammasome activation, we first infected hGBP1 KO cells
that re-express hGBP1 WT or the R48A or G68A mutant with
C. trachomatis. We then examined infection-dependent NLRP3
activation by monitoring the speck formation of the inflamma-
some adaptor ASC (apoptosis-associated Speck-like protein
containing a caspase activation and recruitment domain). In
line with the previous experiments, G68A mutants formed fewer
ASC specks compared with hGBP1 WT-expressing cells (Fig-
ures 3D and 3E). To verify that NLRP3 is themajor inflammasome
pathway induced by C. trachomatis infection, we treated the
cells with the NLPR3 inhibitor MCC950. MCC950 treatment
largely abolished infection-induced IL-1b secretion and pyropto-
sis (Figure S2A). The effect of MCC950 was also confirmed in a
culture of human primary macrophages (Figure S2B).
Next, we asked whether caspase-4 activation causes NLRP3
inflammasome activation. Transient knockdown of caspase-4
inhibited IL-1b release and cell death in response to intracellular
lipopolysaccharide (LPS), a well-established activator of cas-
pase-4 (Figure S2C) (Shi et al., 2014). In contrast, caspase-4
knockdown had no effect on IL-1b secretion and pyroptosis
following C. trachomatis infection (Figure S2C). Taken together,
these results suggest that hGBP1-mediated consecutive hydro-
lysis of GTP to GMP is required for the canonical caspase-4-in-
dependent activation of the NLRP3 inflammasome.
Uric Acid (UA) Synthesis Is Required for Inflammasome
Activation upon Chlamydia Infection
We next investigated the potential mechanism by which hGBP1
promotes NLRP3 inflammasome activation. Several intracellular
danger patterns are known to activate the NLRP3 inflamma-
some, among which UA is one (Braga et al., 2017; Kimball
et al., 2019; Martinon et al., 2006). Interestingly, GMP can be
catabolized to UA through three enzymatic steps (Figure 4A).
We, thus, reasoned that hGBP1 oligomerization on the vacuolar
membrane would result in a local rise in GMP concentration.
Subsequently, this could favor catabolism to UA, which in turn
would activate the NLRP3 inflammasome.An essential prediction of our model is that enzymes involved
in themetabolism of GMP to UAwould be localized to the PCV or
regulated during infection. Indeed, as Chlamydia are obligate
intracellular pathogens, many metabolites and metabolic en-
zymes are known to be hijacked from the host system and re-
cruited to the inclusion membrane (Saka and Valdivia, 2010).
We examined the localization of xanthine oxidase, a key enzyme
involved in the last step of xanthine oxidization to UA. In unin-
fected cells, xanthine oxidase was evenly distributed throughout
the cell. In contrast, this enzyme displayed a marked vesicular
pattern in infected cells, which strongly co-localized with the in-
clusions (Figure S3A). Furthermore, based on our microarray
data from a previous study, we observed that the transcripts of
guanine deaminase (GDA), which catalyzes the upstream step
of xanthine oxidase, are significantly increased upon C. tracho-
matis infection (Mehlitz et al., 2010). qRT-PCR of GDA validated
these microarray results (Figure S3B).
Next, we asked if blocking UA synthesis can impair inflam-
masome activation in response to C. trachomatis infection.
First, we used allopurinol, a clinically approved xanthine oxi-
dase inhibitor used for gout medication. Remarkably, co-treat-
ment of cells with allopurinol mitigated C. trachomatis-induced
pyroptosis and ASC speck formation in a concentration-depen-
dent manner (Figures 4B and S3C). Accordingly, we detected a
sharp reduction of IL-1b secretion in the cell supernatant (Fig-
ure 4B), whereas IL-1b expression was not affected at the
mRNA level (Figure S3D). Allopurinol blocked inflammasome
activation in human primary macrophages as well (Figure S3F).
Importantly, the effect of allopurinol was specific to C. tracho-
matis infection because it had no effect on other inflammasome
activators, such as poly (dA:dT), flagellin, and LPS/ATP (Figures
S3E and S3F). As a second approach, we genetically inacti-
vated the metabolic pathway of UA production. To this end,
we transiently knocked down the enzyme GDA due to its spe-
cific involvement in GMP catabolism rather than that of AMP.
The efficient downregulation of GDA after small interfering
RNA (siRNA) transfection was validated by qRT-PCR (Fig-
ure S4A). Compared with control scrambled siRNA, all three
GDA siRNAs significantly inhibited cell death and increased
ASC speck formation and IL-1b secretion upon infection with
C. trachomatis (Figures 4C and S4B); IL-1b mRNA expression
was unaffected (Figure S4C). Notably, GDA knockdown did
not reduce bacterial growth, indicating that the impaired inflam-
masome activation is not an indirect effect of a lower bacterial
load (Figure S4D).
hGBP1-Produced GMP Is Metabolized to UA
To verify our hypothesis, we measured UA concentrations upon
C. trachomatis infection in THP-1 cells. We observed an infec-
tion-dependent increase of UA in parental cells as well as of
hGBP1 WT-expressing cells, whereas hGBP1 KO cells, R48A
mutants, and G68A mutants showed no induction of UA (Fig-
ure 4D). Next, we applied an antibody against UA, which was
originally generated for the diagnostics of rheumatic arthritis.
We observed a strong UA immunostaining around early
C. trachomatis vacuoles as well as around mature inclusions
that spread throughout the cytoplasm (Figure S4E). UA staining
was abolished in allopurinol-treated cells, confirming theCell Reports 31, 107667, May 19, 2020 5
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Figure 4. hGBP1 Mediates Inflammasome
Activation by Uric Acid
(A) Metabolic pathway of GMP degradation to uric
acid. The enzyme GDA was knocked down by
siRNA, and the enzyme xanthine oxidase was in-
hibited with the chemical compound allopurinol.
(B and C) LDH release and IL-1b ELISA of THP-1
cells treated with increasing concentrations of
allopurinol (50, 100, and 500 mM) (B) or transfected
with control or three different siRNAs against GDA
(C). The cells were stimulated with IFNg + LPS and
infected with C. trachomatis at an MOI of 30 for 24
h; n = 3; two-way ANOVA.
(D) Fold change of UA concentrations in the cell
culture supernatants of infected THP-1 cells
versus non-infected THP-1 cells. The cells were
stimulated with IFN-g + LPS and infected with
C. trachomatis at an MOI of 30 for 24 h; n = 3; one-
way ANOVA.
(E and F) IL-1b ELISA and LDH release of hGBP1
KO THP-1 cells, which were infected with
C. trachomatis at anMOI of 30 for 24 h and treated
with increasing concentrations of guanine or
guanosine (0.5 mM and 1 mM); n = 3; statistical
significance was determined in comparison to the
parental cell line by two-way ANOVA.
All error bars indicate SEM. *p < 0.05, **p < 0.01,
***p < 0.001. See also Figures S3 and S4.
Report
ll
OPEN ACCESSspecificity of the antibody (Figure S4E). UA has been associated
with NLRP3 activation by triggering mitochondrial reactive oxy-
gen species (ROS) production (Braga et al., 2017). Consistently,
we observed an increase of mitochondrial ROS in C. trachoma-
tis-infected cells, which was abolished thereof by allopurinol
treatment (Figure S4F). Lastly, we asked whether infection-
induced inflammasome activation could be rescued in hGBP1
KO cells and G68A mutants by feeding back intermediate me-
tabolites of UA catabolism (Figure 4A). Remarkably, the addition
of guanine and guanosine to hGBP1 KO cells and G68A mutant
cells led to a dose-dependent increase of IL-1b secretion and
pyroptosis (Figures 4E, 4F, S4G, and S4H).
In summary, we propose that hGBP1-mediated inflamma-
some activation occurs through consecutive cleavage of GTP
to GMP, leading to local accumulation of UA, consequently acti-
vating the NLRP3 inflammasome.6 Cell Reports 31, 107667, May 19, 2020DISCUSSION
In this study, we generated a specific cat-
alytic mutant of hGBP1 that retains coop-
erative GTP hydrolysis (i.e., at a compara-
ble rate to the WT protein), while being
impaired in the consecutive hydrolysis
step. By using this mutant, we explored
hGBP1’s unique function in GMP produc-
tion by using an infection model with the
obligate intracellular pathogen C. tracho-
matis. hGBP1 has been implicated in
restricting pathogenic growth and medi-
ating inflammasome activation. Here,
we show that the GTPase activity ofhGBP1 tightly coordinates these two functions. Thus, similar to
other dynamin-related proteins, recruitment of hGBP1 to the
PCV is thought to activate GTP hydrolysis, which may be linked
to membrane remodeling and the destruction of the PCV
(Daumke and Praefcke, 2016; Meunier et al., 2014). We demon-
strate that GMP, produced in the succeeding second nucleotide
cleavage step, then serves as a precursor of UA. In this scenario,
the PCV acts as a platform that mediates the recruitment of
hGBP1 and xanthine oxidase to the C. trachomatis inclusions
to initiate inflammasome signaling.
At the same time, C. trachomatis infection led to an increase in
GDA expression (Figure S1C). Thus far, it has been unclear
whether this regulation of nucleotide metabolizing enzymes is
merely part of a host defense mechanism or a way of
C. trachomatis to redirect the host metabolism as part of a sur-
vival strategy. Downregulation of GDA did not affect pathogenic
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required for the survival of C. trachomatis under regular
conditions. However, the loss of hGBP1-mediated GMP produc-
tion reduced C. trachomatis-induced cell death, implying a
direct link between guanine catabolism and inflammasome acti-
vation. Although we ruled out the contribution of hGBP2 to
C. trachomatis-dependent UA formation, we cannot exclude
the possibility for other hGBPs that can execute this second hy-
drolysis step.
Mouse macrophages use multiple inflammasome pathways in
response to C. trachomatis infection (Finethy et al., 2015).
Conversely, our study indicates that the UA-NLRP3 axis is
mainly responsible for the host response toC. trachomatis infec-
tions in humans. Furthermore, our data suggest that inflamma-
some activation in human macrophages is rather independent
of PAMP liberation by hGBPs, substantiating the finding that
inflammation occurs over a unified pathway. Therefore, we pro-
pose that allopurinol could be a potential therapeutic application
for reducing acute inflammation in patients suffering from
C. trachomatis infection. In the future, it might be useful to test
whether inflammasome activation is triggered by the same
pathway in response to other obligate intracellular pathogens.STAR+METHODS
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Antibodies
Rat monoclonal anti hGBP1 Santa Cruz Biotechnology Cat#sc-53857; RRID:AB_2109333
Goat polyclonal anti-MOMP Bio-Rad (formerly AbD serotec) Cat#1990-0804; RRID:AB_620522
Rabbit polyclonal anti-Caspase-1 Cell Signaling Technology Cat#2225S; RRID:AB_2243894
Rabbit polyclonal anti-Caspase-4 Cell Signaling Technology Cat# 4450; RRID:AB_1950386
Rabbit polyclonal anti-ASC Proteintech Cat# 10500-1-AP; RRID:AB_2174862
Mouse monoclonal anti-Xanthine Oxidase Santa Cruz Biotechnology Cat#sc-398548
Rabbit polyclonal anti UA Abcam Cat# ab53000; RRID:AB_883382
Bacterial and Virus Strains
lentiCRISPR v2 Sanjana et al., 2014 Addgene #52961
plenti CMV GFP Hygro Campeau et al., 2009 Addgene # 17446
lentiCRISPR v2-hGBP1-KO This paper N/A
Plenti CMV GFP Hygro hGBP1 WT This paper N/A
Plenti CMV GFP Hygro hGBP1 R48A This paper N/A
Plenti CMV GFP Hygro hGBP1 G68A This paper N/A
C. trachomatis, serovar L2 ATCC VR-902B
Chemicals, Peptides, and Recombinant Proteins
Phorbol 12-Myristate 13-Acetate Sigma-Aldrich Cat# 524400, CAS 16561-29-8
Human recombinant IFN-g Merck Millipore Cat# IF002
Human recombinant M-CSF Sigma Cat# M6518
LPS, E. Coli O111:B4 Merck Millipore Cat# LPS25
Flagellin AdipoGen Cat#AG-40B-0025-C010
Poly (dA:dT) Sigma Cat#P0883-10UN
MCC950 AbMole Bioscience Cat#M6164, CAS210826-40-7
Z-DEVD-FMK Selleckchem Cat#S7312
IM54 Cayman Chemical Company Cat#13323
Necrostatin-1 AbMole Bioscience Cat#M2315. CAS 4311-88-0
Ferrostatin-1 Adooq Bioscience Cat#A13247, CAS 347174-05-4
Bafilomycin A1 abcam Cat#ab120497
Allopurinol Cayman Chemical Company Cat# 10012597, CAS 315-30-0
Critical Commercial Assays
Plasmid Mini Prep Kit Jena Bioscience PP-204L
Plasmid Midi Prep Kit QIAGEN 12183
CytoTox-ONE Homogeneous Membrane Integrity Assay Promega G7890
Uric Acid/Uricase Assay kit Cell Biolabs, inc. STA-375
MitoSOX Red Mitochondrial Superoxide Indicator Thermo Fisher Scientific Cat#M36008
Human IL-1 beta/IL-1F2 DuoSet ELISA kit R&D Biosystems DY201
FuGENE HD Transfection Reagent Promega E2311
Profect-P1-lipid based protein delivery reagent Targeting Systems #0041
Lipofectamine RNAiMAX Transfection Reagent Thermo Fisher Scientific 13778075
Experimental Models: Cell Lines
THP-1 ATCC TIB-202
HEK293T ATCC CRL-11268
Hela229 ATCC CCL-2.1
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REAGENT or RESOURCE SOURCE IDENTIFIER
THP-1 hGBP1 KO GFP This paper N/A
THP-1 hGBP1 KO +hGBP1 G68A This paper N/A
THP-1 hGBP1 KO +hGBP1 R48A This paper N/A
THP-1 hGBP1 KO +hGBP1 WT This paper N/A
THP-1 hGBP2 shRNA Al-Zeer et al., 2013 N/A
Experimental Models: Organisms/Strains
C. trachomatis, serovar L2 ATCC VR-902B
Oligonucleotides
SiRNA targeting sequence GDA #70 Thermo Fisher Scientific Cat# 4392420, silencer select , s18470
SiRNA targeting sequence GDA #71 Thermo Fisher Scientific Cat# 4392420, silencer select , s18471
SiRNA targeting sequence GDA #72 Thermo Fisher Scientific Cat# 4392420, silencer select , s18472
siRNA targeting sequence CAS4 #1 Thermo Fisher Scientific Cat#4390824, silencer select , s2413
siRNA targeting sequence CAS4 #2 Thermo Fisher Scientific Cat#4390824, silencer select , s2414
hGBP1 KO Primer fw: CACCGACAAAGAGACGATAGCCCCC This paper N/A
GBP KO primer rv: AAACGGGGGCTATCGTCTCTTTGTC This paper N/A
qPCR primer actin fw: CAT GTA CGT TGC TAT CCA GGC This paper https://pga.mgh.harvard.edu/primerbank/
qPCR primer actin rv: CTC CTT AAT GTC ACG CAC GAT This paper https://pga.mgh.harvard.edu/primerbank/
qPCR primer GDA fw: TGA AGC CCA TAG TGA CAC CAC This paper https://pga.mgh.harvard.edu/primerbank/
qPCR primer GDA rv: GCA AAT CAC GGG TTT TAG CAA T This paper https://pga.mgh.harvard.edu/primerbank/
qPCR primer IL-1b fw: CAG GCT GCT CTG GGA TTC TC This paper https://pga.mgh.harvard.edu/primerbank/
qPCR primer IL-1b rv: CCT GGA AGG AGG AGC ACT
TCA TCT
This paper https://pga.mgh.harvard.edu/primerbank/
Recombinant DNA
pSKB-LNB2-hGBP1 This paper N/A
pSKB-LNB2-hGBP1 G68A This paper N/A
pSKB-LNB2-hGBP1 R48A This paper N/A
pSKB-LNB2-hGBP1 K76A This paper N/A
lentiCRISPR v2 Sanjana et al., 2014 Addgene #52961
plenti CMV GFP Hygro Campeau et al., 2009 Addgene #17446
lentiCRISPR v2-hGBP1-KO This paper N/A
plenti CMV GFP Hygro hGBP1 WT This paper N/A
plenti CMV GFP Hygro hGBP1 R48A This paper N/A
plenti CMV GFP Hygro hGBP1 G68A This paper N/A
Software and Algorithms
ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/
Protein Calculator N/A http://protcalc.sourceforge.net/
Primer bank Wang and Seed, 2003 https://pga.mgh.harvard.edu/primerbank/
citation.html
UCSF Chimera (Pettersen et al., 2004) https://www.cgl.ucsf.edu/chimera/
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Oliver
Daumke (oliver.daumke@mdc-berlin.de).
Materials Availability
All plasmids and cell lines generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement.e2 Cell Reports 31, 107667, May 19, 2020
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
THP-1 cell lines (American Type Culture Collection TIB-202) were cultured in RPMI 1640 with 10% fetal bovine serum (FBS). hGBP1
knock-out cell lines were generated by transfection of lentiCRISPRv2 containing hGBP1 single guide RNA sequences and single cell
dilution. hGBP1 WT and mutant cell lines were generated by infection with lentiviruses generated in HEK293T cell line (ATCC CRL-
11268) expressing hGBP1 proteins.
Human Primary Macrophages
Human primary macrophages were isolated from peripheral bloodmononuclear cells (PBMCs) from healthy female donors, aged 20-
40 years according to protocol number EA1/203/16 as approved by the ethics commission of Charite´, Berlin. Human primary mac-
rophages were cultured by adherence from PBMCs in RPMI 1640 with 10% FBS and 50 ng/ml human macrophage colony-stimu-
lating factor (M-CSF) for 6 d.
Microbe strain and culture
C. trachomatis serovar L2 (ATCC VR-902B) was routinely, cultured, prepared, and propagated in HeLa cells (American Type Culture
Collection CCL-2.1) as previously described (Al-Zeer et al., 2013).
METHOD DETAILS
Expression constructs
The hGBP1mutants, R48A, K76A andG68A, were generated using the plasmid pQE80L-hGBP1 (a kind gift fromGerrit Praefcke) and
the QuikChange site-directed mutagenesis kit (Stratagene, USA). The PCR product was cloned into amodified pET28 vector (pSKB-
LNB2) and the mutation was verified by DNA sequencing.
Protein preparation
WT and mutant hGBP1 variants with an N-terminal His6 tag were expressed using pSKB-LNB2 in E. coli strain BL21(DE3). The cells
were grown at 37C in TB medium, and protein expression was induced at an optical density of 0.6-0.8 by the addition of 50 mM iso-
propyl-b-d-thiogalactopyranoside (IPTG), followed by overnight incubation at 18C. Upon centrifugation, the cells were suspended in
50 mM Tris–HCl (pH 8.0), 5 mMMgCl2, 500 mM NaCl, 5 mM b-mercaptoethanol, 10% (v/v) glycerol, 20 mM imidazole, 100 mM phe-
nylmethylsulfonyl fluoride (PMSF) (Roth, Germany) and 1 mM DNase I (Roche) and mechanically lysed in a microfluidizer (Microflui-
dics). Following centrifugation (30,0003 g, 1 h, 4C), the protein in the cleared lysate was applied to a NiNTA column (GE Healthcare)
and eluted with 20 mM Tris–HCl (pH 8.0), 5 mMMgCl2, 100 mMNaCl, 5 mM b-mercaptoethanol, 10% glycerol and 20 mM imidazole
using a 20 mM to 500 mM imidazole gradient. It was followed by gel filtration via Superdex 200 (GE healthcare) in 50 mM HEPES pH
7.5, 5 mM MgCl2 and 2 mM dithiothreitol. Fractions containing monomeric hGBP1 were pooled and concentrated using Amicon fil-
ters with a 10 kDa cut-off to 10 mg/ml, shock-frozen in liquid nitrogen and stored at 80C. The concentration of hGBP1 was deter-
mined by ultraviolet spectrophotometry at 276 nm with the calculated molar absorption coefficient of 45,450 M-1 cm-1.
GTP hydrolysis assay
Non-farnesylated hGBP1WT andmutants at the indicated concentrations were incubated with 1 mMGTP at 37C in buffer A (20mM
HEPESpH7.5, 150mMNaCl, 2mMMgCl2). Aliquots of the reactionwere taken at the given time points, diluted in excess buffer A and
flash-frozen in liquid nitrogen. Nucleotides were separated via reversed-phase chromatography (C-18, Hypersil) and their rations
quantified by integration of the 260 nm absorbance.
Cell culture treatments and C. trachomatis infection
Human primary monocyte–derived macrophages (hMDMs) were prepared by adherence from whole-blood fractions of healthy do-
nors. Primary monocytes were cultured in RPMI 1640 with 10% FBS and treated with 50 ng/mlM-CSF for 6 d. THP-1 cells were
cultured in RPMI with 10% FCS. When indicated, THP-1 cells were differentiated with 100 nM phorbol 12-myristate 13-acetate
(PMA) for 24 h.C. trachomatis bacteria were cultured as previously described (Al-Zeer et al., 2013) and infected at MOI 5 for inclusion
count and infectivity assay, or at MOI 30 for inflammasome activation. For allopurinol specificity and inflammasome control exper-
iments, THP-1 cells or hMDMwere transfected either with 1 mg Flagellin (i.e., NLRC4 inflammasome stimulation) or 1 mg poly(dA:dT)
(i.e., AIM2 inflammasome stimulation) for 6 h using Profect P1 reagent (Targeting Systems) or Lipofectamine RNAimax (Invitrogen),
respectively. THP-1 cells or hMDMs were primed for 16 h with 100 nM LPS or 100 nM LPS + 100 nM IFN-g, respectively, and treated
with 5 mM ATP (NLRP3) for 4 h or transfected with 1 mg LPS (CAS4) for 6 h using FuGENE HD transfection reagent (Promega). For
NLRP3 inhibition experiments, THP-1 cells or hMDMs were treated with 300 nM MCC950 for 1 h prior to 24 h infection withCell Reports 31, 107667, May 19, 2020 e3
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OPEN ACCESSC. trachomatis. For cell death pathway determination, THP-1 hGBP1 R48A mutant cells were treated with 12 mM IM-54, 1 mM Bafi-
lomycin-A1, 40 mMnecrostatin-1, 5 mM ferrostatin-1 or 15 mg/ml Ac-YVAD-CMK 1 h prior to 24 h infection withC. trachomatis. For the
metabolite feedback experiments, THP-1 hGBP1 KO cells and THP-1 hGBP1 G68A mutant cells were treated with 0.5 mM or 1 mM
guanine or guanosine for 1 h post infection (p.i.) with C. trachomatis.
CRISPR Cas9 mediated Knock out of hGBP1 in THP-1
hGBP1 single guide RNA sequences from Feng Zhang’s Gecko database were cloned into lentiCRISPR v2 and transfected into THP-
1 cells with Fugene HD transfection reagent (Promega). Two days after transfection, the cells were diluted into single clones and
seeded into 96 well plates. Successful knockout of hGBP1 was confirmed via immunoblotting (rat anti hGBP1 1:1000, Santa Cruz
biotechnology).
Immunostaining and ASC speck count
THP-1 cells were differentiated for 24 h with 100 nM PMA and infected with C. trachomatis at MOI 5 or 30 for 24 h. Cells were fixed in
4%Paraformaldehyde (PFA) or 2% PFA for a specific UA staining. After fixation, the cells were permeabilized with 0.3% Triton X-100
for 10 min and blocked in 3% bovine serum albumin (BSA) in phosphate-buffered saline or 10% horse serum, 100 mM glycine for 1 h
at room temperature. The cells were stained for C. trachomatis inclusions (goat anti-MOMP 1:150), ASC (rabbit anti-ASC 1:300, Pro-
teintech), Xanthine Oxidase (mouse anti XO, 1:50 Santa Cruz biotechnology), hGBP1 (rat anti hGBP1 1:50, Santa Cruz biotech-
nology), rabbit anti uric acid (UA, 1:1500), at 4C, overnight. ASC specks were counted by evaluating 500 cells per experiment.
Inclusion count
THP-1 cells were differentiated with 100 nM PMA for 24 h and stimulated with 100 nM IFN-g, 100 nM LPS for 24 h. The cells were
infected withC. trachomatis atMOI 5. After 1 h of infection, themedia was changed to fresh RPMI, and the cells incubated for another
23 h. The cells were fixed 24 h post infection (p.i.) with 4% PFA and stained for C. trachomatis and 40,6-diamidino-2-phenylindole
(DAPI). The number of inclusions per nuclei was determined following three independent experiments. In each experiment, 500 cells
were evaluated. Significance was determined by one-way ANOVA.
Infectivity assay
Host cells were seeded in 6-well plates, treated as above, infected with C. trachomatis diluted in infectious medium at MOI 5 and
incubated at 35C and 5% CO2. Two hours p.i., the cells were washed and loaded with fresh medium containing 100 U/ml IFN-g.
Control infected cells were not treated with the cytokine. The cell cultures were then incubated as above for 48 h. The formation
of infectious C. trachomatis progeny in a secondary infection was assessed by infectivity titration assay (Al-Zeer et al., 2009). Briefly,
the infected cells were mechanically destroyed using glass beads. Resulting lysates were serially diluted in infectious medium and
then used to inoculate HeLa cells for 2 h. The cells were thenwashed and further incubated for 24 h in RPMImediumwith 5%FBS and
1 mg/ml cycloheximide. One day later, the cells were fixed with 4% PFA and stained for C. trachomatis, as described above. Forty
confocal images were taken per sample and experiment at 400xmagnification, and the area of each image calculated and divided by
the area of one well. The infectivity titer is expressed as the number of inclusions (IFU/ml) IFU/ml = no. inclusions in 10 fields/103 no.
fields in a well 3 dilution factor. Significance was determined by a Student’s t test.
LDH cytotoxicity assay
THP-1 cells (1.7 3 105 per well) or hMDMs (2.0 3 105 per well) were stimulated with 100 nM IFN-g and 100 nM LPS for 16 h and
infected withC. trachomatis at MOI 30 for 24h in a 96-well plate or 24-well plate (hMDMs). LDH release upon infection wasmeasured
using CytoTox-ONE Homogeneous Membrane Integrity Assay kit (Promega, according to manufacturer’s instructions). LDH release
was calculated by subtraction of cell culture background and normalization to average maximum according to the Promega manual.
Significance was determined by two-way ANOVA.
ELISA
THP-1 cells (1.7 3 105 per well) or hMDMs (2.0 3 105 per well) were stimulated with 100 nM IFN-g and 100 nM LPS for 16 h and
infected with C. trachomatis at MOI 30 for 24 h in a 96-well plate or 24-well plate (hMDMs). IL-1b measurements were conducted
using the Human IL-1 beta/IL-1F2 DuoSet ELISA kit according to the manufacturer’s instructions. Significance was determined
by two-way ANOVA.
mtROS measurement
THP-1 cells (23 105 per well) were stimulated with 100 nM IFN-g and 100 nM LPS for 16 h and infected withC. trachomatis at MOI 30
for 24 h in a 96-well plate. Mitochondrial ROS were measured by reaction with MitoSOX Red dye in a microplate reader according to
manufacturer’s instructions (fluorescence Ex.: 400nm/ Em.: 595 nm). Significance was determined by two-way ANOVA.e4 Cell Reports 31, 107667, May 19, 2020
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THP-1 cells (23 105 per well) were stimulated with 100 nM IFN-g and 100 nM LPS for 16 h and infected withC. trachomatis at MOI 30
for 24 h in a 96-well plate. Uric acid concentration in cell culture supernatants was measured using Uric acid/Uricase Assay Kit from
Cell Biolabs, inc. according to the manufacturer’s instructions. Briefly, uric acid reacts with water and oxygen in the presence of the
enzyme uricase to produce allantoin and H2O2. In the presence of HRP, a fluorescence probe reacts with H2O2 in a 1:1 stoichiometry
to produce a highly fluorescent product (Ex.: 535 nm/ Em.: 595 nm), which can be measured using a microplate reader.
QUANTIFICATION AND STATISTICAL ANALYSIS
Image Analysis
For inclusion and ASC speck counting approximately 30-40 images were taken per experiments representing approximately 500
cells. Nuclei,C. trachomatis inclusions and ASC specks weremanually counted from immunostaining and analyzed statistically using
one-way ANOVA in Graphpad Prism software. Infectivity titer was determined by counting C. trachomatis inclusions and nuclei from
40 images per sample and the area of each image calculated and divided by the area of one well. The infectivity titer is expressed as
the number of inclusions (IFU/ml) IFU/ml = no. inclusions in 10 fields/103 no. fields in a well3 dilution factor. Significance was deter-
mined by Student’s t test using Graphpad Prism software.
Cell Biological Assays
ELISA, LDH andmtROS assays were analyzed using two-way ANOVA andUric acid measurements using one-way ANOVA in Graph-
pad Prism software for three independent experiments.Cell Reports 31, 107667, May 19, 2020 e5
